Vis-Rx Prime Micro-Imaging Catheter Study
Completed · NCT06685783
Conditions: Coronary Artery Disease
At a glance
- Research payments reported, 2025
- $103,010
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 34
About the trial
- Sponsor
- Gentuity, LLC
- Dates
- Started 2024-12-11; completion 2025-05-01
- Results posted
- Yes
To study the performance of the Gentuity® HF-OCT (High Frequency Optical Coherence Tomography) Imaging System and Vis-Rx Prime® Micro-Imaging Catheter when used to obtain images of coronary arteries in patients who are undergoing cardiac catheterization and are candidates for interventional procedures. The study will evaluate ease of catheter use by physicians using the catheters, image quality and overall performance. The patient's involvement in the study ends when the cardiac catheterization/interventional procedure is completed.
From ClinicalTrials.gov, last updated 2026-04-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Gentuity, LLC reported $103,010 in research payments for this study in 2025 (18 payments).
Products named: Vis-Rx Prime, Gentuity Hf-Oct Imaging System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Neal Sawlani Interventional Cardiology · Park Ridge, IL
- Evan S. Shlofmitz, DO Interventional Cardiology · Roslyn, NY
- Timothy D. Henry, MD Interventional Cardiology · Cincinnati, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Lindner Center for Research at Christ Hospital $39,875
- Advocate Aurora Research Institute $32,730
- St. Francis Research & Educational Corp $30,405
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.